Loading
A phase 1/2 trial of Rilvegostomig, Cisplatin, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, now recruiting.
A Platform Study in Non-Small Cell Lung Cancer (NSCLC) is a phase 1/2 interventional study registered as NCT06996782 by AstraZeneca, with 152 participants planned, started 2025-11-24 and due to reach its primary completion in 2029-02-23. Interventions recorded: Rilvegostomig, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel. Conditions listed: Advanced or Metastatic Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Ramucirumab, Pemetrexed, Paclitaxel / nab-paclitaxel, AstraZeneca.
Shares Rilvegostomig, Pemetrexed, AstraZeneca, Cisplatin.
Shares Rilvegostomig, Paclitaxel / nab-paclitaxel, AstraZeneca, Carboplatin.
Shares Rilvegostomig, Ramucirumab, AstraZeneca, Small-cell lung cancer.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, AstraZeneca, Carboplatin.
Shares Rilvegostomig, Pemetrexed, AstraZeneca, Cisplatin.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin.